Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-26-114792
Filing Date
2026-10-08
Accepted
2026-10-08 20:59:21
Documents
5
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16637
2 SCHEDULE I (TRANSACTIONS IN THE SECURITIES OF THE ISSUER SINCE AMENDMENT NO. 4) tm2627334d1_ex99-1.htm EX-99.1 17228
3 POWER OF ATTORNEY tm2627334d1_ex99-2.htm EX-99.2 6180
4 POWER OF ATTORNEY tm2627334d1_ex99-3.htm EX-99.3 6248
5 JOINT FILING AGREEMENT tm2627334d1_ex99-4.htm EX-99.4 6701
  Complete submission text file 0001104659-26-114792.txt   54837
Mailing Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001
Business Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001 212-478-0000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 3115 MERRYFIELD ROW SUITE 120 SAN DIEGO CA 92121
Business Address 3115 MERRYFIELD ROW SUITE 120 SAN DIEGO CA 92121 (858) 684-1300
Gossamer Bio, Inc. (Subject) CIK: 0001728117 (see all company filings)

EIN.: 475461709 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91334 | Film No.: 261450973
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)